Fedratinib

證據等級: L5

預測適應症: 10 個

Fedratinib: From Myelofibrosis to Benign PEComa

One-Sentence Summary

Fedratinib (brand name Inrebic) is a selective JAK2 inhibitor approved for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis. The TxGNN model predicts it may be effective for Benign PEComa (Perivascular Epithelioid Cell Neoplasm), with no clinical trials and no published literature currently supporting this specific direction.

Quick Overview

Item	Content
Original Indication	Myelofibrosis (intermediate-2 or high-risk primary/secondary)
Predicted New Indication	Benign PEComa
TxGNN Prediction Score	99.84%
Evidence Level	L5
Singapore Market Status	Not registered
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Fedratinib is a selective JAK2 inhibitor with secondary BRD4 inhibitory activity. Its proven efficacy in myelofibrosis stems from suppression of constitutive JAK2/STAT5 signalling — particularly in patients carrying the JAK2 V617F mutation or MPL/CALR alterations that drive aberrant cytokine receptor signalling.

Benign PEComa belongs to the perivascular epithelioid cell tumour family, which is primarily driven by inactivation of TSC1/TSC2, resulting in mTOR pathway hyperactivation. The clinically established treatment for mTOR-driven PEComas is mTOR inhibitors (e.g., everolimus). There is no direct preclinical evidence that Fedratinib's JAK2 or BRD4 inhibition meaningfully suppresses TSC/mTOR-mediated tumour proliferation.

The high TxGNN prediction score most likely reflects shared co-morbidity nodes or tissue-level topological proximity within the knowledge graph rather than a direct mechanistic bridge. Until preclinical models in PEComa specifically demonstrate sensitivity to JAK2 or BRD4 inhibition, the biological plausibility of this repurposing hypothesis remains unestablished.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Fedratinib is not currently registered in Singapore. No product authorisations are on record.

Cytotoxicity

Fedratinib is a targeted anticancer agent indicated for myelofibrosis, a malignant haematological condition. It meets the criteria for antineoplastic classification.

Item	Content
Cytotoxicity Classification	Targeted therapy (selective JAK2 / secondary BRD4 kinase inhibitor)
Myelosuppression Risk	High — anaemia, thrombocytopenia, and neutropenia are dose-limiting toxicities; CBC monitoring required
Emetogenicity Classification	Moderate — nausea and vomiting are commonly reported; anti-emetic prophylaxis is recommended
Monitoring Items	CBC with differential (weekly for first 3 months, then monthly); liver function tests; renal function; thiamine levels before initiation and periodically thereafter (Wernicke's encephalopathy black-box warning)
Handling Protection	Handle as a cytotoxic oral agent per institutional cytotoxic drug handling guidelines

Safety Considerations

Please refer to the package insert for safety information.

Critical note from evidence pack: Fedratinib carries a black-box warning for Wernicke's encephalopathy (thiamine deficiency-associated). This risk is particularly relevant when considering use in malnourished or hypermetabolic patients. Thiamine status must be assessed and corrected before initiating treatment.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.84%), the mechanistic link between Fedratinib (a JAK2/BRD4 inhibitor) and benign PEComa (an mTOR-driven tumour) is indirect and speculative, with no supporting clinical trials, literature, or preclinical data. An established standard of care (mTOR inhibitors) already exists for this indication.

To proceed, the following is needed:

Preclinical studies in PEComa cell lines or TSC-null tumour models to determine whether JAK2 or BRD4 inhibition has any effect on mTOR-driven proliferation
Full MOA and kinase selectivity profile from DrugBank to identify any secondary targets relevant to PEComa biology
Regulatory strategy assessment: Fedratinib is currently unregistered in Singapore; a regulatory pathway would need to be identified before any clinical development
Thiamine monitoring protocol to be built into any clinical or compassionate-use plan given the black-box warning
Priority note: Consider evaluating HLH-associated indications (ranks 8–9 in this report, evidence level L4) as a nearer-term repurposing opportunity, given class-effect support from ruxolitinib (JAK1/2) in the same pathway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.